Corn trypsin inhibitor decreases tissue-type plasminogen activator-mediated fibrinolysis of human plasma

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 3, 2009, Pages 191-196

  Nielsen, Vance G ^a,b,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Basic Medical Research II   (United States)

Author keywords

Corn trypsin inhibitor; Fibrinolysis; Plasminogen; Thrombelastography; Tissue type plasminogen activator

Indexed keywords

ALPHA 2 ANTIPLASMIN; CORN TRYPSIN INHIBITOR; INFUSORIAL EARTH; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; TRYPSIN INHIBITOR; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTICLE; BLOOD CLOT; BLOOD CLOT LYSIS; BLOOD CLOTTING; BLOOD CLOTTING TIME; CONTROLLED STUDY; DRUG MECHANISM; FIBRINOLYSIS; GROWTH INHIBITION; HUMAN; KINETICS; LIFESPAN; PARTIAL THROMBOPLASTIN TIME; PLASMA; PRIORITY JOURNAL; THROMBOCYTE; THROMBOELASTOGRAPHY;

BLOOD COAGULATION; DIATOMACEOUS EARTH; FIBRINOLYSIS; HUMANS; KINETICS; PLANT PROTEINS; PLASMINOGEN ACTIVATORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 67650924559     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283258011     Document Type: Article

References (22)

1. Swartz MJ, Mitchell HL, Cox DJ, Reeck GR. Isolation and characterization of trypsin inhibitor from opaque-2 corn seeds.J Biol Chem 1977; 252:8105-8107.
2. Hojima Y, Pierce JV, Pisano JJ. Hageman factor fragment inhibitor in corn seeds: purification and characterization. Thromb Res 1980; 20:149-162.
3. Ratnoff OD, Moneme V. Inhibition of ellagic acid-activated Hageman factor (factor XII) and Hageman factor fragments by popcorn inhibitor. Proc Soc Exp Biol Med 1981; 166:297-299.
4. Mahoney WC, Hermodson MA, Jones B, Powers DD, Corfman RS, Reeck GR. Amino acid sequence and secondary structural analysis of the corn inhibitor of trypsin and activated Hageman factor. J Biol Chem 1984; 259:8412-8416.
5. Kambhu SA, Ratnoff OD, Everson B. Inhibition of Hageman factor (factor XII) by popcorn inhibitor. J Lab Clin Med 1985; 105:625-628.
6. Behnke CA, Yee VC, Le Trong I, Pedersen LC, Stenkamp RE, Kim S, et al. Structural determinants of the bifunctional corn Hageman factor inhibitor: X-ray crystal structure at 1.95 Åesolution. Biochemistry 1998; 37:15277-15288.
7. Chen ZY, Brown RL, Russin JS, Lax AR, Cleveland TE. A corn trypsin inhibitor with antifungal activity inhibits Aspergillus flavus a-amylase. Phytopathology 1999; 89:902-907.
8. Fischer TH, Thatte HS, Nichols TC, Bender-Neal DE, Bellinger AD, Vournakis JN. Synergistic platelet integrin signaling and factor XII activation in poly-N-acetyl glucosamine fiber-mediated hemostasis. Biomaterials 2005; 26:5433-5443.
9. van Veen JJ, Gatt A, Cooper PC, Kitchen S, Bowyer AE, Makris M. Corn trypsin inhibitor in fluorogenic thrombin-generation measurements is only necessary a low tissue factor concentrations and influences the relationship between factor VIII coagulant activity and thrombogram parameters. Blood Coagul Fibrinolysis 2008; 19:183-189.
10. Luddington R, Baglin T. Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition. J Thromb Haemost 2004; 2:1954-1959.
11. Latacha MP, Schaiff WT, Eisenberg PR, Abendschein DR. Factor XII-dependent increases in thrombin activity induce carboxypeptidase-mediated attenuation of pharmacological fibrinolysis. J Thromb Haemost 2004; 2:128-134.
12. Rivard GE, Brummel-Ziedins KE, Mann KG, Fan L, Hofer A, Cohen E. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost 2005; 3:2039-2043.
13. Nielsen VG, Steenwyk BL, Gurley WQ. Contact activation prolongs clot lysis time in human plasma: role of thrombin activatable fibrinolysis inhibitor and factor XIII. J Heart Lung Transplant 2006; 25:1247-1252.
14. Nielsen VG, Steenwyk BL, Holman WL, Kirklin JK, Parks DA, Zhou F, et al. Mechanical circulatory device thrombosis: a new paradigm linking hypercoagulation and hypofibrinolysis. ASIAO J 2008; 54:351-358.
15. Nielsen VG, Cohen BM, Cohen E. Elastic modulus-based thrombelastographic quantification of plasma clot fibrinolysis with progressive plasminogen activation. Blood Coagul Fibrinolysis 2006; 17:75-81.
16. 2-antiplasmin to antifibrinolytic activity in human plasma. Blood Coagul Fibrinolysis 2007; 18:29-33.
17. Nielsen VG. Clot lifespan model analysis of clot growth and fibrinolysis in normal subjects: role of thrombin activatable fibrinolysis inhibitor. Blood Coagul Fibrinolysis 2008; 19:283-287.
18. Nielsen VG. Hydroxyethyl starch enhances fibrinolysis in human plasma by diminishing a2-antiplasmin-plasmin interactions. Blood Coagul Fibrinolysis 2007; 18:647-656.
19. Nielsen VG, Audu P, Cankovic L, Lyerly RT III, Steenwyk BL, Armstead VE, et al. Qualitative thrombelastographic method of detection of tissue factor in human plasma. Anesth Analg 2007; 104:59-64.
20. Nielsen VG, Kirklin JK. Argatroban enhances fibrinolysis by differential inhibition of thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor and Factor XIII. Blood Coagul Fibrinolysis 2008; 19:793-800.
21. McMullen BA, Fujikawa K. Amino acid sequence of the heavy chain of human a-factor XIIa (activated Hageman factor). J Biol Chem 1985; 260:5328-5341.
22. Nielsen VG, Cankovic L, Steenwyk BL. Epsilon aminocaproic acid inhibition of fibrinolysis in vitro: should the 'therapeutic' concentration be reconsidered? Blood Coagul Fibrinolysis 2007; 18:35-39.